The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Completed · Phase 3

Conditions studied: Alzheimer's Disease

In brief

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

Key facts

Study ID

NCT00090116

Run by

Forest Laboratories

People needed

400

Starts

2003-03-01

Expected to finish

2005-03-01

Last updated by the study team

2012-03-05

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of moderate to severe Alzheimer's disease;
• ambulatory patients

You may not qualify if…

• folate deficiency;
• clinically significant central nervous system disease other than Alzheimer's disease;
• clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease

Where it is running

• Pivotal Research Centers — Peoria, Arizona, United States
• 21st Century Neurology — Phoenix, Arizona, United States
• Margolin Brain Institute — Fresno, California, United States
• Pharmacology Research Institute — Northridge, California, United States
• UCI Medical Center — Orange, California, United States
• Pacific Research Network — San Diego, California, United States
• Affiliated Research Institute — San Diego, California, United States
• University of Colorado Health Sciences Center — Denver, Colorado, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Baumel-Eisner Neuromedical Institute — Fort Lauderdale, Florida, United States
• Berma Research Group — Hialeah, Florida, United States
• Palm Beach Neurological Center — Palm Beach Gardens, Florida, United States
• Neurology Clinical Research, Inc. — Plantation, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Palm Beach Neurology — West Palm Beach, Florida, United States
• Indiana Universisty Medical Center — Indianapolis, Indiana, United States
• Lexington Clinic — Lexington, Kentucky, United States
• J. Gary Booker, MD — Shreveport, Louisiana, United States
• Mood and Memory Clinic of Michigan — Farmington Hills, Michigan, United States
• St. Louis University — St Louis, Missouri, United States
• Alzheimer's Research Corporation — Lakehurst, New Jersey, United States
• Joel Ross, MD — Long Branch, New Jersey, United States
• Ubhc/Umdnj — Piscataway, New Jersey, United States
• Upstate Clinical Research — Albany, New York, United States
• Nathan S. Kline Institute for Psychiatric Research — Orangeburg, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.